hyperopia - To be honest the business model was always sound to me. We just had crappy leaders in the past. I always knew the model would be slow in sales until we landed bigger contracts and embedded ourselves with trials. We are finally just seeing the beginning of the fruits of the labor. I am excited to see what news we get in 2018. My hope is more trials and more FDA approvals and more commercialization.
I think right now through end of year will see price $9-11 just based on current revenue and value. The potential to go higher will be once we start to see new revenue numbers at end of year, and if we get any more FDA approvals on trails in 2018. I don't have high expectations for 4Q as we all herd that KITE/GILD is ramping up the commercialization it wont be instant, but I expect increase in numbers through 4Q and first half of 2018.
The good news with the increasing rev numbers is that the 21 month cash flow number I provided will continue to extend until we don't need to ever worry about cash. I think we are close to that at this point.
News 
Market Data 
Discover 
